



Software for  
Business Intelligence

**BizInt Smart Charts**

# Workshop: Create Reports Integrating Your Key Sources

*John Willmore*

*2023 PIUG Annual Conference*

*30 April 2023*


# Agenda

- What we do
- Roadmap
- Exports
- Reference Rows
- Sources
- Questions and Requests

# How do I create reports with BizInt Smart Charts?

Export search results to BizInt Smart Charts.

Do your searches on supported databases and hosts...



BizInt Smart Charts is Windows software installed on your desktop.

# BizInt Smart Charts extracts the key data elements...

# ...and builds tabular reports.

PatBase search results interface showing multiple search results for a query. The interface includes a search bar, filters, and a list of results with details like publication number, date, and title.

**Export - Bizint**

You are about to export all 1,500 results.

**Selections**

- ☒ All 1,500 results
- ☐ Top 3 results per query (3 total)

**Export** **Cancel**

**Patent families (FamPat) - 3 results**

#	Publication number	1st app. date	Applicant/Assignee	100%
(1)	US267135	2014-06-30	HARVARD CO...	100%
(2)	EP3071698	2014-06-30	HARVARD CO...	100%
(3)	US267135	2014-11-11	ZYMERGEN	100%

	Title	Patent Family	Patent	Kind	Date	Image	Abstract	Probable Assignee	Claims	Status
1	COMPOSITIONS AND METHODS FOR TARGETED GENE DISRUPTION IN PROKARYOTES	US 2015079193 US 2015113223 US 2015353901	A1 A1 A1	2015-05-14 2015-05-14 2015-12-10			Source US2015113223  The present disclosure relates to engineered bacteriophage vector compositions comprising nucleic acids that express recombinant nucleases. Also provided are methods of using engineered bacteriophage vectors to effect genomic disruption or targeted gene disruption in prokaryotes. [CONT]	RADIANT GENOMICS INC.	US2015122533A	DEAD
2	LARGE GENE EXCISION AND INSERTION	US 2015166964 US 12978678 WO 2015077290 US 2015077290 CA 2920828 AU 2014353100 KR 20160078502 EP 3071698 EP 3071698 EP 3071698 EP 3045443 JP 2016537892 JP 202006033 WV 122930 EP 3071698 GB 2754498	A1 B2 A1 A1 A1 A1 A1 A1 A1 A1 T1 T2 A1 A1 T3 T3	2015-05-21 2009-09-29 2015-05-28 2015-08-06 2015-06-15 2015-06-15 2016-07-04 2016-09-28 2016-09-28 2019-09-04 2020-02-05 2016-12-08 2020-04-23 2015-01-17 2018-11-18 2020-04-17		Methods of simultaneously excising large nucleic acid sequences from a target nucleic acid and inserting large foreign nucleic acid sequences into the target nucleic acid sequence using DNA binding protein nucleases are described.	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	US10786488	ALIVE	
3	RNA-GUIDED TRANSCRIPTIONAL REGULATION	US 2014356959 US 2014356955 US 9297135 US 2016127450 US 2020024518 US 10640799 US 10767914 US 2020027372 US 2016187558 WO 2014978768 AU 2914613 AU 2014274039 AU 2014274039 AU 2020029972	A1 A1 B A1 A1 A1 A1 A1 A1 A1 A1 A1 A1	2014-12-04 2014-12-04 2012-02-23 2016-02-23 2020-02-23 2016-09-19 2020-09-08 2020-09-24 2016-02-11 2015-03-12 2016-09-04 2016-01-07 2020-03-19 2020-07-09		Methods of modulating expression of a target nucleic acid in a cell are provided including introducing into the cell a first foreign nucleic acid encoding one or more RNAs complementary to DNA, wherein the DNA includes the target nucleic acid, introducing into the cell a second foreign nucleic acid encoding a nuclease, and a third protein that binds to the DNA and is guided by the [CONT]	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	US10647898	ALIVE	
<b>Agents:</b>										
Designated states: AE AG AL AM AT AU AZ BA BB BG BR BS CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI FR GB GR GT GU HK HN HU ID IL IN IS JP KE KG KH KR LA LV LY MA MC MD ME MG MK MN MY NM NZ NO NP NT NU OX PA PE PG PH PL PT RO RS RU SA SD SE SG SI SK SL SV SN SR ST SU SW SY TD TH TJ TM TR TT TZ UA UG UK US UY UZ VN WO ZA ZM ZW										
CPC: C12N 2766/00 A1; C12N 2766/00 B1; C12N 2766/00 C1; C12N 2766/00 D1; C12N 2766/00 E1; C12N 2766/00 F1; C12N 2766/00 G1; C12N 2766/00 H1; C12N 2766/00 I1; C12N 2766/00 J1; C12N 2766/00 K1; C12N 2766/00 L1; C12N 2766/00 M1; C12N 2766/00 N1; C12N 2766/00 O1; C12N 2766/00 P1; C12N 2766/00 Q1; C12N 2766/00 R1; C12N 2766/00 S1; C12N 2766/00 T1; C12N 2766/00 U1; C12N 2766/00 V1; C12N 2766/00 W1; C12N 2766/00 X1; C12N 2766/00 Y1; C12N 2766/00 Z1										
Search 2 "VINCE" 1 of 1										
Display results										
Title Pub No. Kind Pub Date State Status Est Expiry Patent Assignee Inventor(s) Abstract										
1	RNA-guided transcriptional regulation	US 9297135 US 2014356955 US 2016127450 US 10640799 US 2020024518 US 2014356959 US 2020029972	B2 A1 A1 A1 A1 A1 A1	2012-02-23 2014-12-04 2016-02-23 2020-02-23 2016-09-19 2020-09-08 2020-09-24	ALIVE ALIVE ALIVE ALIVE ALIVE ALIVE PENDING	2034-06-04 2034-06-04 2034-06-04 2034-06-04 2034-06-04 2034-06-04 2034-06-04	HARVARD COLLEGE	CHURCH GEORGE M ML PRASHANT G ESVELT KEVIN M	(US9297135)  Methods of modulating expression of a target nucleic acid in a cell are provided including introducing into the cell a first foreign nucleic acid encoding one or more RNAs complementary to DNA, wherein the DNA includes the target nucleic acid, introducing into the cell a second foreign nucleic acid encoding a nuclease-null Cas9 protein that binds to the DNA and is guided by the one or [CONT]	
2	Large gene excision and insertion	EP 3071698 EP 3071698 EP 3045443 WO 201577290 US 10787684 US 20150140654 JP 2016537892 JP 202006033 DK 3071698 ES 2754498 CA 2920828 AU 2014353100 KR 20160078502	B1 A2 A1 A2 B2 A1 A1 A1 A1 A1 A1 A1 A1	2009-09-24 2016-09-28 2015-05-28 2015-05-28 2018-06-06 2015-05-21 2016-12-08 2020-04-23 2019-11-18 2018-11-18 2015-05-28 2016-06-02 2016-07-04	ALIVE ALIVE PENDING LAPSED ALIVE GRANTED PENDING PENDING GRANTED GRANTED GRANTED PENDING PENDING	2034-11-19 2034-11-19 2034-11-19 2034-11-19 2034-11-19 2034-06-30 2034-11-19 2034-11-19 2034-11-19 2034-11-19 2034-11-19 2034-11-19 2034-11-19	HARVARD COLLEGE	BYRNE SUSAN M CHURCH GEORGE M	(EP3071698)  Methods of simultaneously excising large nucleic acid sequences from a target nucleic acid and inserting large foreign nucleic sequences into the target nucleic acid sequence using DNA binding protein nucleases are described.	
3	Compositions and methods for targeted gene disruption in prokaryotes	WO 2015079193 US 2015113223 US 2015353901	A1 A1 A1	2015-05-14 2015-05-						

	Title	Patent Family			Patent Assignee	Abstract	Therapeutic Activity	Technology Focus
		Patent	Kind	Date				
1	Altering a target nucleic acid in a cell by introducing into the cell a first foreign nucleic acid encoding guide RNA sequences complementary to DNA, and introducing into the cell a second foreign nucleic acid encoding a Cas9 protein	US 2016010664 WO 2015072290 AU 2015072290 CA 3020629 AU 2014531300 KR 2016078502 EP 3071698 AU 2016537882 EP 3071698 HK 1229380 EP 3071698 EP 3004543 JP 202002033 ES 2754498 US 10776846	A1 A2 A1 A1 A1 A2 A1 B1 A A T3 B2	2015-05-21 2015-08-06 2015-05-29 2016-06-02 2016-07-04 2016-09-28 2016-12-08 2017-06-28 2017-11-17 2019-09-04 2020-02-05 2020-04-23 2020-04-17 2020-09-29	HARVARD COLLEGE BYRNE S M CHURCH G M	Alteration of a target nucleic acid in a cell comprises introducing into the cell a first foreign nucleic acid encoding one or more guide RNA sequences complementary to DNA, where the DNA-encoding target nucleic acid, introducing into the cell a second foreign nucleic acid encoding a Cas9 protein that binds to the DNA and is guided by the one or more guide RNA sequences, introducing into the cell a third foreign nucleic acid encoding an exogenous nucleic acid sequence to be included into the target nucleic acid sequence. [CONT.]	Antibacterial. Immunosuppressive. Anti-inflammatory. No biological data given.	Preferred Method: In altering the target nucleic acid in the cell, the exogenous nucleic acid sequence to be included into the target nucleic acid sequence is flanked by sequences complementary to the area around the gene replacement. The exogenous nucleic acid is between greater than 100 base pairs and about 150000 base pairs in length. The first nucleic acid sequence of interest is between greater than 100 base pairs and about 10000 base pairs in length [CONT.]
2	New bacteriophage comprises polynucleotide expressing RNA-directed DNA-binding polypeptide comprising nuclease module, and targeting module comprising guide RNA, for restricting growth of host cell, and for preparing antisense composition	US 20160353901	A1	2015-12-10	RADIANT GENOMICS INC.	A bacteriophage comprising a polynucleotide that expresses: (a) an RNA-directed DNA-binding polypeptide comprising a nuclease module; and (b) a targeting module comprising a guide RNA, where the targeting module features the RNA-directed DNA-binding polypeptide to a target DNA sequence within a prokaryotic host cell, thus producing a double-strand break within the target sequence is new. [CONT.]	Antibacterial. Immunosuppressive. Anti-inflammatory. No biological data given.	Preferred Bacteriophage: In the bacteriophage, the prokaryotic host cell is an antibiotic-resistant host cell and the target DNA sequence is within a gene that confers resistance to the antibiotic. The prokaryotic host cell is of a species selected from Escherichia coli, Acinetobacter baumannii, Enterococcus faecalis, Enterococcus faecium, Pseudomonas aeruginosa, Staphylococcus aureus. [CONT.]
3	Modulating expression of a target nucleic acid comprises providing to the cell a guide RNA including a transcriptional activator or repressor domain as a fusion protein, and providing to the cell a Cas9 protein	US 2016035959 US 9267135	A1 B2	2014-12-04 2016-02-23	HARVARD COLLEGE CHURCH G M EDELTM K M MALIP G	Modulating expression of a target nucleic acid in a cell comprises providing to the cell a guide RNA complementary to the target nucleic acid sequence including a transcriptional activator or repressor domain as a fusion protein for modulating target nucleic acid expression in vivo; and providing to the cell a nuclease nucleic acid that interacts with the guide RNA and binds to the target nucleic acid sequence in a site specific manner. [CONT.]	Antibacterial. Immunosuppressive. Anti-inflammatory. No biological data given.	Preferred Method: In the method modulating expression of a target nucleic acid in a cell, the guide RNA including the transcriptional activator or repressor domain as a fusion protein is provided to the cell by introducing to the cell a guide RNA encoding the target nucleic acid sequence including the transcriptional activator or repressor domain as fusion protein, where the Cas9 protein is provided to the [CONT.]

**Derwent™**  
A Clarivate Analytics company

<div> <div> <div></div> <div></div> <div></div> </div> <div> <div></div> <div></div> <div></div> </div> </div>	3	RNA-guided transcriptional regulation	GQPAT Gold+ Proteins	US 201401000000 US 202000000000 US 9267135 US 201401000000
--	---	---------------------------------------	----------------------	---

Title	Patent Family			Patent Assignee	Inventor(s)	Seq. ID Number	Query Pct Identity	Subject Length	Patent Sequence Location
	Patent	Kind	Date						
1 LARGE GENE EXCISION AND INSERTION	WO2015072290 AU2014351300 CA3020629 DK3071698 EP3071698 EP3004543 JP2016537882 KR2016078502 US2016078502 US2016104954	A1 A2 A1 A1 A1 A1 A1 A1 A1 A1	20150529	HARVARD UNIVERSITY BYRNE SUSAN M CHURCH GEORGE M	WO2014072290-0001	100.00	1368	probable disclosure not found by automated parsing	
2 RNA-guided transcriptional regulation	US9267135 US2014035959 US2014035959 US2014359959 US2014359959 US20160237456 US2016237456 US20200024618	A1 A1 A1 A1 A1 A1 A1 A1	20160223	HARVARD UNIVERSITY Church George M MALIP Prashant G Evelat Kevin M	US9267135-0001	100.00	1368	probable disclosure not found by automated parsing	
3 RNA Guided Transcriptional Regulation	US20200024618 US2014035959 US2014035959 US2014359959 US2014359959 US20160237456 US2016237456 US9267135	A1 A1 A1 A1 A1 A1 A1 A1	20200123	HARVARD COLLEGE CHURCH GEORGE M MALIP PRASHANT G EVELAT KEVIN M	US20200024618-0001	100.00	1368	probable disclosure not found by automated parsing	
4 RNA-guided Transcriptional Regulation	US20160237456 US2014035959 US2014035959 US2014359959 US2014359959 US20160237456 US20200024618 US9267135	A1 A1 A1 A1 A1 A1 A1 A1	20160818	HARVARD UNIVERSITY Church George M MALIP Prashant G Evelat Kevin M	US20160237456-0001	100.00	1368	probable disclosure not found by automated parsing	
5 Compositions and Methods for Targeted Gene Disruption in Prokaryotes	US20150135391 US20150132263 US2016078163	A1 A1 A1	20151210	RADIANT GENOMICS, INC.	LIU OLIVER Kim Jeffrey	US20160353901-0002	100.00	1368	claim 19, 20

# Related records are identified automatically...

	Title	Database	Common Family	Patent Family			State	Patent Assignee
				Patent	Kind	Date		
1	New bacteriophage comprises polynucleotide expressing RNA-directed DNA-binding polypeptide comprising nuclease module, and targeting module comprising guide RNA, for restricting growth of host cell, and for preparing antiseptic composition	Derwent Innovation + DWPI	WO 2015070193	US 20150353901	A1	2015-12-10		RADIANT GENOMICS INC
2	New bacteriophage comprising polynucleotide that expresses RNA-directed DNA-binding polypeptide and targeting module comprising guide RNA, used e.g. for treating autoimmune and inflammatory disease, and disease caused by bacterial infection	Derwent Innovation + DWPI	WO 2015070193	US 20150132263 WO 2015070193	A1 A1	2015-05-14 2015-05-14		KIM J LIU O RADIANT GENOMICS INC
3	Compositions and methods for targeted gene disruption in prokaryotes	FAMPAT	WO 2015070193	WO 2015070193 US 20150132263 US 20150353901	A1 A1 A1	2015-05-14 2015-05-14 2015-12-10	DEAD	ZYMERGEN
4	Compositions and Methods for Targeted Gene Disruption in Prokaryotes	GQPAT Gold+ Proteins	WO 2015070193	US20150353901 US20150132263 WO2015070193		20151210		RADIANT GENOMICS, INC.
5	COMPOSITIONS AND METHODS FOR TARGETED GENE DISRUPTION IN PROKARYOTES	GQPAT Gold+ Proteins	WO 2015070193	US20150132263 US20150353901 WO2015070193		20150514		RADIANT GENOMICS; RADIANT GENOMICS INC
6	COMPOSITIONS AND METHODS FOR TARGETED GENE DISRUPTION IN PROKARYOTES	PatBase	WO 2015070193	WO 2015070193 US 2015132263 US 2015353901	A1 A A	2015-05-14 2015-05-14 2015-12-10	DEAD	KIM JEFFREY LIU OLIVER RADIANT GENOMICS INC

*Common Patent Family tool assigns a Common Family number to related publications.*

# Further integrate your data...

	Title	Database	Patent Family			Probable Assignee	FTO Family with Expiry						Sequence Locations			
			Patent	Kind	Date		Pub No.	Kind	Pub Date	State	Status	Est Expiry	Seq. ID #	% Identity	Length	Location
1 a	COMPOSITIONS AND METHODS FOR TARGETED GENE DISRUPTION IN PROKARYOTES	PatBase	WO 2015070193 US 2015132263 US 2015353901	A1 A A	2015-05-14 2015-05-14 2015-12-10	RADIANT GENOMICS INC										
1 b	Compositions and methods for targeted gene disruption in prokaryotes	FAMPAT	WO 201570193 US 20150132263 US 20150353901	A1 A1 A1	2015-05-14 2015-05-14 2015-12-10	ZYMERGEN	WO 201570193 US 20150132263 US 20150353901	A1 A1 A1	2015-05-14 2015-05-14 2015-12-10	DEAD DEAD DEAD	LAPSED LAPSED LAPSED	2017-05-11 2016-10-11 2016-10-03				
1 c	Compositions and Methods for Targeted Gene Disruption in Prokaryotes	GQPAT Gold+ Proteins	US20150353901 US20150132263 WO2015070193		20151210								US20150353901-0002	100.00	1368	claim: 19; 20
1 d	COMPOSITIONS AND METHODS FOR TARGETED GENE DISRUPTION IN PROKARYOTES	GQPAT Gold+ Proteins	US20150132263 US20150353901 WO2015070193		20150514								US20150132263-0002	100.00	1368	claim: 19; 20
1 e	New bacteriophage comprises polynucleotide expressing RNA-directed DNA-binding polypeptide comprising nuclease module, and targeting module comprising guide RNA, for restricting growth of host cell, and for preparing antiseptic composition	Derwent Innovation + DWPI	US 20150353901	A1	2015-12-10											
1 f	New bacteriophage comprising polynucleotide that expresses RNA-directed DNA-binding polypeptide and targeting module comprising guide RNA, used e.g. for treating autoimmune and inflammatory disease, and disease caused by bacterial infection	Derwent Innovation + DWPI	US 20150132263 WO 2015070193	A1 A1	2015-05-14 2015-05-14											

Use the Reference Rows tool to select key data for each set of related records, based on your rules and selections.

# And create a single integrated row...

Title	Database	Patent Family			Probable Assignee	FTO Family with Expiry						Sequence Locations					
		Patent	Kind	Date		Pub No.	Kind	Pub Date	State	Status	Est Expiry	Seq. ID #	% Identity	Length	Location		
1. New bacteriophage comprises polynucleotide expressing RNA-directed DNA-binding polypeptide comprising nuclease module, and targeting module comprising guide RNA, for restricting growth of host cell, and for preparing antiseptic composition	1a Patbase   link	WO 2015070193	A1	2015-05-14	RADIANT GENOMICS INC	WO 2015070193	A1	2015-05-14	DEAD	LAPSED	2017-05-11	US20150353901-0002	100.00	1368	claim: 19; 20	1c	
	1b FAMPAT   link	US 2015132263	A	2015-12-10		US 2015132263	A	2015-05-14	DEAD	LAPSED	2016-10-11	US20150132263-0002	100.00	1368	claim: 19; 20	1d	
	1c GPATPRT   link	US 2015353901	A	2015-12-10													
	1d GPATPRT   link																
	1e Innov   link											WO 2015070193	A1	2015-05-14	DEAD	LAPSED	2017-05-11
	1f Innov   link											US 20150132263	A1	2015-05-14	DEAD	LAPSED	2016-10-11
												US 20150353901	A1	2015-12-10	DEAD	LAPSED	2016-10-03
		1e Innov			1a Patbase		1a Patbase					1b FAMPAT					
2. Modulating expression of a target nucleic acid comprises providing to the cell a guide RNA including a transcriptional New bacteriophage comprises polynucleotide expressing RNA-directed DNA-binding polypeptide comprising nuclease module, and targeting module comprising guide RNA, for restricting growth of host cell, and for preparing antiseptic composition	2a Patbase   link	US 9267135	B2	2016-02-23	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	US 9267135	B2	2016-02-23	ALIVE	GRANTED	2034-06-04	US20160237456-0001	100.00	1368	probable disclosure (not found by automated parsing)	2c	
	2b FAMPAT   link	US 20140356959	A1	2014-12-04		US 20140356959	A1	2014-12-04									
	2c GPATPRT   link	US 10640789	B2	2020-05-05		US 10640789	B2	2020-05-05	ALIVE	GRANTED	2034-06-04	US20140356959-0001	100.00	1368	probable disclosure (not found by automated parsing)	2d	
	2d GPATPRT   link	US 20160237456	A1	2016-08-18		US 20160237456	A1	2016-08-18									
		0767194	B2	2020-09-08		US 10767194	B2	2020-09-08	ALIVE	GRANTED	2034-06-04						
		0200024618	A1	2020-01-23		US 20200024618	A1	2020-01-23				US9267135-0001	100.00	1368	probable disclosure (not found by automated parsing)	2e	
		0140356956	A1	2014-12-04		US 20140356956	A1	2014-12-04	ALIVE	PENDING	2034-06-04						
		0200299732	A1	2020-09-24		US 20200299732	A1	2020-09-24	ALIVE	PENDING	2034-06-04	US20140356956-0001	100.00	1368	probable disclosure (not found by automated parsing)	2f	
												US20200024618-0001	100.00	1368	probable disclosure (not found by automated parsing)	2g	
	2h Innov			2b FAMPAT		2a Patbase					2b FAMPAT						
3. Altering a target nucleic acid in a cell by introducing into the cell a first foreign nucleic acid encoding guide RNA sequences complementary to DNA, and introducing into the cell a second foreign nucleic acid encoding a Cas9 protein	3a Patbase   link	US 2015140664	A	2015-05-21	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	EP 3071698	B1	2019-09-04				AU2014353100-0001	100.00	1368	probable disclosure (not found by automated parsing)	3c	
	3b FAMPAT   link	US 10787684	B	2020-09-29		EP 3071698	A2	2016-09-28	ALIVE	GRANTED	2034-11-19						
	3c GPATPRT   link	WO 2015077290	A2	2015-05-28		EP 3071698	A4	2017-06-28				JP2016537982-0001	100.00	1368	probable disclosure (not found by automated parsing)	3d	
	3d GPATPRT   link	WO 2015077290	A3	2015-08-06		EP 3604543	A1	2020-02-05	ALIVE	PENDING	2034-11-19						
	3e GPATPRT   link	CA 2930828	AA	2016-05-16		WO 201577290	A2	2015-05-28	DEAD	LAPSED	2017-05-19						
	3f GPATPRT   link	AU 2014353100	AA	2016-06-02		WO 201577290	A3	2015-08-06				CA2930828-0001	100.00	1368	probable disclosure (not found by automated parsing)	3e	
	3g GPATPRT   link	KR 20160078502	A	2016-07-04		US 10787684	B2	2020-09-29	ALIVE	GRANTED	2034-06-30						
	3h GPATPRT   link	EP 3071698	A2	2016-09-28		US 20150140664	A1	2015-05-21				EP3071698-0001	100.00	1368	probable disclosure (not found by automated parsing)	3f	
	3i GPATPRT   link	EP 3071698	A4	2017-06-28		JP 2016537982	A	2016-12-08	ALIVE	PENDING	2034-11-19						
	3j GPATPRT   link	EP 3071698	B1	2019-09-04		JP 2020062033	A	2020-04-23	ALIVE	PENDING	2034-11-19						
	3j GPATPRT   link	EP 3604543	A1	2020-02-05		DK 3071698T	T3	2019-11-18	ALIVE	GRANTED	2034-11-19	EP3604543-0001	100.00	1368	probable disclosure (not found by automated parsing)	3g	
	3k Innov   link	JP 2016537982	T2	2016-12-08		ES 2754498	T3	2020-04-17	ALIVE	GRANTED	2034-11-19						
		JP 2020062033	A2	2020-04-23		CA 2930828	A1	2015-05-28	ALIVE	PENDING	2034-11-19	US20150140664-0001	100.00	1368	probable disclosure (not found by automated parsing)	3h	
		HK 1229380	A1	2017-11-17		AU 2014353100	A1	2016-06-02	ALIVE	PENDING	2034-11-19						
		DK 3071698	T3	2019-11-18		KR 20160078502	A	2016-07-04	ALIVE	PENDING	2034-11-19	KR1020160078502-0001	100.00	1368	probable disclosure (not found by automated parsing)	3i	
		ES 2754498	T3	2020-04-17								WO2015077290-0001	100.00	1368	probable disclosure (not found by automated parsing)	3j	
	3k Innov			3a Patbase		3a Patbase					3b FAMPAT						

...for each family in

US20150353901-0002	100.00	1368	claim: 19; 20	
US20150132263-0002	100.00	1368	claim: 19; 20	

# See what is new and changed in updated reports...

	Title	FTO Family				Patent Assignee	Inventor(s)	Abstract
		Pub No.	Kind	Pub Date	Status			
1	Methods and compositions for sequences guiding cas9 targeting	W O2015112896	A2	2015-07-30		NORTH CAROLINA STATE UNIVERSITY	BARRANGOU RODOLPHE SELLE KURT M BRINER ALEXANDRAE	(WO2015112896) The present invention is directed to methods and compositions for genome editing and DNAtargeting of proteins
		W O2015112896	A3	2015-10-29				
		W O2015112896	A9	2015-11-26				
2	Rna modification to engineer cas9 activity	W O2015200555	A2	2015-12-30		CARIBOU BIOSCIENCES	MAY ANDREW PAUL DONOHUE PAUL NYE CHRISTOPHER SLORACH EUAN HAURWITZ RACHEL	(WO2015200555) The disclosure provides for compositions, methods and kits, for reducing off-target effects of genome engineering. In one aspect, a composition is provided comprising an engineered nucleoprotein complex. [CONT.]
		W O2015200555	A3	2016-03-10				
3	Crispr-cas-related methods, compositions and components for cancer immunotherapy	W O2015161276	A2	2015-10-22		EDITAS MEDICINE	WELSTEAD G GRANT FRIEDLAND ARI E MAEDER MORGAN L BUMCROT DAVID A	(WO2015161276) CRISPR/Cas-related composition and methods for treatment of cancer, in particular by using gRNA molecules comprising a targeting domain which is complementary with a target domain from the PAs, BID, CTLA4, PDCC1, CBLB, PTPN6, TRAC or TRBC gene. In some embodiments, gRNAs are used with Cas9 enzymes to cause a cleavage event in said genes within engineered chimeric antigen receptor (CAR) T cells [CONT.]
		W O2015161276	A3	2015-12-10				
4	Crisprcas-related methods and compositions for treating cystic fibrosis	W O2015157070	A2	2015-10-15		EDITAS MEDICINE	REYON DEEPAK MAEDER MORGAN L FRIEDLAND ARI E WELSTEAD G GRANT BUMCROT DAVID A	(WO2015157070) CRISPR/CAS-related compositions and methods for treatment of Cystic Fibrosis (CF).
		W O2015157070	A3	2015-12-30				

Update your existing report...




New records and changes in updated records are highlighted.

	Title	Row Status	Patent Assignee	FTO Family				Inventor(s)	New Publications
				Pub No.	Kind	Pub Date	Status		
1	Method for producing genome-edited plants using plant virus vectors	Added	NATIONAL AGRICULTURE & FOOD RESEARCH ORGANIZATION	WO 2018151155	A1	2018-08-23	LAPSED	ISHIBASHI Kazuhiro	WO 2018151155 A1
				US 20190359993	A1	2019-11-28	PENDING	ARIGA Hirotaka	US 20190359993 A1
				JP 2018151155W	A1	2019-12-12	PENDING	TOKI Seichi KAYA Hidetaka	JP 2018151155
2	Dna writers, molecular recorders and uses thereof	Added	MIT - MASSACHUSETTS INSTITUTE OF TECHNOLOGY US NAVY	WO 2018152197	A1	2018-08-23	LAPSED	FARZADFARD FAHIM	WO 2018152197 A1
				US 20200063127	A1	2020-02-27	PENDING	LU TIMOTHY	US 20200063127 A1
3	RNA-guided transcriptional regulation	Added	HARVARD COLLEGE	US 9267135	B2	2016-02-23	GRANTED	CHURCH GEORGE M	US 9267135 B2
				US 20140356959	A1	2014-12-04		MALI PRASHANT G	US 20140356959 A1
				US 10640789	B2	2020-05-05	GRANTED	ESVELT KEVIN M	US 10640789 B2
				US 20160237456	A1	2016-08-18			US 20160237456 A1
				US 10767194	B2	2020-09-08	GRANTED		US 10767194 B2
				US 20200024618	A1	2020-01-23			US 20200024618 A1
				US 20140356956	A1	2014-12-04	PENDING		US 20140356956 A1
				US 20200299732	A1	2020-09-24	PENDING		US 20200299732 A1
4	Compositions and methods for targeted gene disruption in prokaryotes	Updated	ZYMERGEN	WO 201570193	A1	2015-05-14	LAPSED	LIU OLIVER	
				US 20150132263	A1	2015-05-14	LAPSED	KIM JEFFREY	
				US 20150353901	A1	2015-12-10	LAPSED		
5	Large gene excision and insertion	Updated	HARVARD COLLEGE	EP 3071698	B1	2019-09-04		BYRNE SUSAN M	EP 3071698 B1
				EP 3071698	A2	2016-09-28	GRANTED	CHURCH GEORGE M	EP 3071698 A2
				EP 3071698	A4	2017-06-28			EP 3071698 A4
				EP 3604543	A1	2020-02-05	PENDING		EP 3604543 A1
				WO 201577290	A2	2015-05-28	LAPSED		US 10787684 B2
				WO 201577290	A3	2015-08-06			JP 2016537982 A
				US 10787684	B2	2020-09-29	GRANTED		JP 2020062033 A
				US 20150140664	A1	2015-05-21			DK 3071698
				JP 2016537982	A	2016-12-08	PENDING		ES 2754498
				JP 2020062033	A	2020-04-23	PENDING		CA 2930828 A1
				DK 3071698T	T3	2019-11-18	GRANTED		AU 2014353100 A1
				ES 2754498	T3	2020-04-17	GRANTED		KR 20160078502 A
				CA 2930828	A1	2015-05-28	PENDING		
				AU 2014353100	A1	2016-06-02	PENDING		
				KR 20160078502	A	2016-07-04	PENDING		

...with new data.

	Title	Patent Assignee	FTO Family				Inventor(s)	International Patent Class
			Pub No.	Kind	Pub Date	Status		
1	RNA-guided transcriptional regulation	HARVARD COLLEGE	US 9267135	B2	2016-02-23	GRANTED	CHURCH GEORGE M	C12N-009/22
			US 20140356959	A1	2014-12-04		MALI PRASHANT G	C12N-015/01
			US 10640789	B2	2020-05-05	GRANTED	ESVELT KEVIN M	C12N-015/10
			US 20160237456	A1	2016-08-18			C12N-015/11
			US 10767194	B2	2020-09-08	GRANTED		C12N-015/113
			US 20200024618	A1	2020-01-23			C12N-015/115
			US 20140356956	A1	2014-12-04	PENDING		C12N-015/63
			US 20200299732	A1	2020-09-24	PENDING		C12N-015/66
								C12N-015/65
								C12N-015/67
								C12N-015/60
2	Dna writers, molecular recorders and uses thereof	MIT - MASSACHUSETTS INSTITUTE OF TECHNOLOGY US NAVY	WO 2018152197	A1	2018-08-23	LAPSED	FARZADFARD FAHIM	C12N-009/22
			US 20200063127	A1	2020-02-27	PENDING	LU TIMOTHY	C12N-009/78
								C12N-015/11
								C12N-015/62
								C12N-015/63
								C12N-015/65
3	Method for producing genome-edited plants using plant virus vectors	NATIONAL AGRICULTURE & FOOD RESEARCH ORGANIZATION	WO 2018151155	A1	2018-08-23	LAPSED	ISHIBASHI Kazuhiro	A01H-001/00
			US 20190359993	A1	2019-11-28	PENDING	ARIGA Hirotaka	C12N-005/10
			JP 2018151155W	A1	2019-12-12	PENDING	TOKI Seichi KAYA Hidetaka	C12N-005/14
								C12N-015/09
								C12N-015/82
4	Large gene excision and insertion	HARVARD COLLEGE	EP 3071698	B1	2019-09-04		BYRNE SUSAN M	A61K-038/43
			EP 3071698	A2	2016-09-28	GRANTED	CHURCH GEORGE M	C07H-021/02
			EP 3071698	A4	2017-06-28			C07H-021/04
			EP 3604543	A1	2020-02-05	PENDING		C12N-009/14
			WO 201577290	A2	2015-05-28	LAPSED		C12N-009/22
			WO 201577290	A3	2015-08-06			C12N-009/52
			US 10787684	B2	2020-09-29	GRANTED		C12N-015/00
			US 20150140664	A1	2015-05-21			C12N-015/09
			JP 2016537982	A	2016-12-08	PENDING		C12N-015/10
			JP 2020062033	A	2020-04-23	PENDING		C12N-015/63
			DK 3071698T	T3	2019-11-18	GRANTED		C12N-015/64
			ES 2754498	T3	2020-04-17	GRANTED		C12N-015/90
			CA 2930828	A1	2015-05-28	PENDING		C12Q-001/68
			AU 2014353100	A1	2016-06-02	PENDING		
			KR 20160078502	A	2016-07-04	PENDING		

...and send the refined data back to your BizInt Smart Charts report.



# And deliver IP reports targeted to your needs.

	Drug Name(s)	Database	Enhanced Title	Probable Assignee	Patent Family			Indications
					Patent	Kind	Date	
1.	mRNA-1653	1a <a href="#">CortPat</a>   <a href="#">link</a> 1b <a href="#">CDDI</a>   <a href="#">link</a> 1c <a href="#">Patbase</a>   <a href="#">link</a>	Vaccines comprising RNA polynucleotides encoding human metapneumovirus or human parainfluenza virus 3 F proteins co-formulated with lipids - useful in treating metapneumovirus and parainfluenza virus infections.	MODERNATX INC	WO 2018107088 WO 2018107088 EP 3551193 EP 3551193 US 2020069794 HK 40016413	A2 A3 A2 A4 A A1	2018-06-14 2018-07-12 2019-10-16 2020-08-19 2020-03-05 2020-09-11	Infection, metapneumovirus (MPV) Infection, parainfluenza virus
	1b CDDI		1a <a href="#">CortPat</a>	1c <a href="#">Patbase</a>	1c <a href="#">Patbase</a>			1b CDDI
2.	R-6717	2a <a href="#">CortPat</a>   <a href="#">link</a> 2b <a href="#">CDDI</a>   <a href="#">link</a> 2c <a href="#">Patbase</a>   <a href="#">link</a>	Stabilized mRNA comprising at least one coding region encoding antigenic peptide derived from glycoprotein precursor or nucleoprotein of Lassa virus useful for treating Lassa virus	CUREVAC AG	WO 2018115525 EP 3558354	A1 A1	2018-06-28 2019-10-30	Lassa fever
	2b CDDI		2a <a href="#">CortPat</a>					
3.	PR/8 HA-DVG	3a <a href="#">CortPat</a>   <a href="#">link</a> 3b <a href="#">CDDI</a>   <a href="#">link</a> 3c <a href="#">Patbase</a>   <a href="#">link</a>	In vitro-trans polypeptide immunostimulating cancer					
	3b CDDI		3a <a href="#">CortPat</a>					
4.	CV-9202	4a <a href="#">CortPat</a>   <a href="#">link</a> 4b <a href="#">CDDI</a>   <a href="#">link</a> 4c <a href="#">Patbase</a>   <a href="#">link</a>	Composition combination lung cancer.					
	4b CDDI		4a <a href="#">CortPat</a>					
5.	mRNA-1440 mRNA-1851	5a <a href="#">CortPat</a>   <a href="#">link</a> 5b <a href="#">CDDI</a>   <a href="#">link</a> 5c <a href="#">Patbase</a>   <a href="#">link</a>	Nucleic acid encoding H7 formulated w influenza inf					
	5b CDDI		5a <a href="#">CortPat</a>					
6.	EBOV mature GP (IgK-membrane bound)	6a <a href="#">CortPat</a>   <a href="#">link</a> 6b <a href="#">CDDI</a>   <a href="#">link</a> 6c <a href="#">Patbase</a>   <a href="#">link</a>	Ebola virus (polynucleotide terminal cap EBOV infect					
	6b CDDI		6a <a href="#">CortPat</a>					

Drug Name(s)	Enhanced Title	Probable Assignee	Patent Number	Indications
1 mRNA-1653 {1b CDDI}	Vaccines comprising RNA polynucleotides encoding human metapneumovirus or human parainfluenza virus 3 F proteins co-formulated with lipids - useful in treating metapneumovirus and parainfluenza virus infections. {1a CortPat}	MODERNATX INC {1c Patbase}	WO 2018107088 A2 {1c Patbase}	Infection, metapneumovirus (MPV) Infection, parainfluenza virus {1b CDDI}
2 R-6717 {2b CDDI}	Stabilized mRNA comprising at least one coding region encoding antigenic peptide derived from glycoprotein precursor or nucleoprotein of Lassa virus $\hat{a}e^a$ useful for treating Lassa virus infection. {2a CortPat}	CUREVAC AG {2c Patbase}		
3 PR/8 HA-DVG {3b CDDI}	In vitro-transcribed RNA molecule encoding an antigen polypeptide (influenza hemagglutinin) and an immunostimulatory RNA activating RIG-1 - useful for treating cancer or pathogenic infections. {3a CortPat}	HARVARD COLLEGE {3c Patbase}		
4 CV-9202 {4b CDDI}	Compositions comprising at least one mRNA encoding a combination of antigens - useful for treating non-small cell lung cancer. {4a CortPat}	CUREVAC AG {4c Patbase}		
5 mRNA-1440 mRNA-1851 {5b CDDI}	Nucleic acid vaccine containing an RNA polynucleotide encoding H7N9 and HA10 hemagglutinin antigens formulated within a lipid nanoparticle $\hat{a}e^a$ useful for treating influenza infections. {5a CortPat}	MODERNATX INC {5c Patbase}		

1.	Title: New aryl sulfoxide derivatives useful for controlling animal pests in crop protection, material protection and/or in veterinary sector
	Database: Derwent World Patents Index <a href="#">PatBase</a>
	Use: (I) or the composition is useful for controlling animal pests in crop protection, material protection and/or in the veterinary sector (claimed).
	Probable Assignee: BAYER CROSCIENCE AG
	Patent Family:
	Patent Kind Date
	<a href="#">WO 2014202510</a> A1 2014-12-24
	TW 201536739 A 2015-10-01
	Hyperlinks: <a href="#">Source</a> <a href="#">WO 2014202510 A1</a> <a href="#">PatDocs Family Tree</a>

Espacenet  
Patent search

Office/Language

My Espacenet Help Classification search Results ☒ Popup tips Report data error Feedback

Home > Results > WO2018107088A2

1. >

**WO2018107088A2** RESPIRATORY VIRUS NUCLEIC ACID VACCINES

Available in Patent Translate

Bibliographic data

Register
Global Dossier

Applicants MODERNATX INC [US] +  
Inventors CIARAMELLA GIUSEPPE [US]; HIMANSU SUNNY [US] +

Classifications  
IPC A61K31/7105;  
CPC A61K31/7105 (EP,US); A61K31/7115 (EP,US); A61K38/164 (EP,US); A61K39/12 (EP); A61K39/295 (EP,US); A61K47/26 (US); A61K9/0019 (EP); A61K9/0051 (US); A61K9/5146 (US); A61P31/14 (EP); A61P31/16 (EP); C12N15/86 (US);

Cotton rat viral load - HMPV challenge

*We make tables*



## *Highlights of What's New*

- Reload of sequence databases on STNext
- Virtual databases on GenomeQuest
- Fixed bunches of bugs in Word exports
- Quick open for statistics and exports
- Reference Rows preview button
- Delete user-added columns
- Hide multiple columns at once
- New content in Pharmaprojects and Trialtrove

## *Version 5.8 (Coming real soon)*

VERSION

5.8

- New exports to Word, Excel, HTML
- Choice of style for all exports (and custom styles too)
- Attribution options in Reference Rows exports
- Support for new PatBase XML (with hit highlights)
- Bug fixes for PatBase, GenomeQuest, STNext



# *Roadmap for First Half 2023*

- Export improvements (Word and HTML and Excel)
- PatBase XML enhancements (w/ hit highlights)
- Add support for PatSnap ?
- Rework create, combine, and update workflows (summer)

VERSION 5.8

VERSION 5.8

## *Roadmap for Second Half 2023*

- STN Chemistry: MARPAT, Reaxys, DCR, image quality  
Variations on “index of hit structures”
- Subtable editing support
- More export capabilities
- Never-ending campaign of database improvements



Software for  
Business Intelligence

**BizInt Smart Charts**

THE JOURNEY CONTINUES...

# How Do I Deliver My Search Results?

Matt Eberle & Diane Webb  
Tuesday 9:15am




# Agenda

- What we do
- Roadmap
- **Exports**
- Reference Rows
- Sources
- Questions and Requests

# Export and Statistics Workflow Improvements

- New option to directly open the export or statistics without having to specify a file name
- Creates a file in your temporary directory
- Excel exports open without warning messages





Generic Statistics Options

Specify how values are separated in this column:

- ☒ Separate lines
- ☐ Semi-colon (,)
- ☐ Spaces
- ☐ Count entire cell as one value

Open Save Cancel



HTML Export Options

You can control the format of the generated HTML using the options below.

Page

- ☐ Include link (after title)  
Text:   
Link:  File...  
Style: BizInt Modern - clean updated format

Chart


- ☐ Split chart into smaller HTML tables
- ☒ Convert URLs to links
- ☒ Include highlights
- ☐ Display subtables as a single cell
- ☒ Include links to publisher website

Records

- ☐ Include records \*
- ☐ Include images in records

(\* Distribution or publication of database records is subject to the terms of your agreements with the database provider.)

Open Save Cancel




# Export and Statistics Workflow Improvements

- **The old behavior is still available...**  
just hit the middle button
- Asks you for a file name
- File and directory of images created

**Generic Statistics Options**

Specify how values are separated in this column:

☒ Separate lines  
☐ Semi-colon (;)  
☐ Spaces  
☐ Treat the cell as one value



**HTML Export Options**

You can control the format of the generated HTML using the options below.

Page


☐ Include link (after title)  
Text:   
Link:    
Style:

Chart

☐ Split chart into smaller HTML tables  
☒ Convert URLs to links  
☒ Include highlights  
☐ Display subtables as a single cell  
☒ Include links to publisher website

Records

☐ Include records \*  
☐ Include images in records  
(\* Distribution or publication of database records is subject to the terms and conditions of the license agreements with the database provider.)



## *Export changes*

VERSION

5.8

- Choice of stylesheet for almost every export type
- Easily customized presentation (colors, fonts, etc)
- More consistent internal link names
- Fixing a LOT of glitches in export to Word
- Excel: alignment formatting, column header options

# Export changes

VERSION

5.8

- Export panels have been reorganized
- Some options have been removed (text/link at top of table)
- Option to not include chart title



**HTML Export Options**

You can control the format of the generated HTML using the options below.

Style: BizInt Plum - plum color scheme

**Chart**

- ☐ Split chart into smaller HTML tables
- ☒ Convert URLs to links
- ☒ Include highlights
- ☐ Display subtables as a single cell
- ☒ Include links to publisher website
- ☒ Include chart title

**Records**

- ☒ Include records \*
- ☐ Include images in records

(\* Distribution or publication of database records is subject to the terms of your agreements with the database provider.)

Open Save Cancel

# Export changes

VERSION

5.8

- New (and updated) styles
- Easy to add custom styles  
(**we can make them for you**)
- Same styles available in HTML, Word, Excel
- Reference Rows uses same styles

**HTML Export Options**

You can control the format of the generated HTML using the options below.

Style: BizInt Plum - plum color scheme

Chart: BizInt Blue - dark blue color scheme  
BizInt Classic - former 'BizInt Modern'  
**BizInt Plum - plum color scheme**  
BizInt Scaled - former 'BizInt Modern Scaled'  
BizInt Teal - teal color scheme

☐ Split cells  
☒ Convert URLs to links  
☒ Include highlights  
☐ Display subtables as a single cell  
☒ Include links to publisher website  
☒ Include chart title

Records

☒ Include records \*  
☐ Include images in records

(\* Distribution or publication of database records is subject to the terms of your agreements with the database provider.)

Open Save Cancel

# Export changes

VERSION

5.8

Word

Excel

Title		Database	Probable Assignee	Inventor(s)	Patent Family Patent	Kind	Date	Abstract
1	Modulating expression of a target nucleic acid comprises providing to the cell a guide RNA including a transcriptional activator or repressor domain as a fusion protein, and providing to the cell a nuclease null Cas9 protein	1a	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	CHERCH DZHORDZH M	US 9267135	B2	2016-02-23	(US9267135)
		1b		CHURCH GEORGE M	US 20140356959	A1	2014-12-04	Methods of modulating expression of a target nucleic acid in a cell are provided including introducing into the cell a first foreign nucleic acid encoding one or more
		1c		ESVELT KEVIN M	US 10640789	B2	2020-05-05	RNAs complementary to DNA, wherein the DNA includes the target nucleic acid, introducing into the cell a second foreign
		1d		GEORGE M CHURCH	US 20160237456	A1	2016-08-18	
		1e		KEVIN M ESVELT	US 10767194	B2	2020-09-08	
		1f		KEVIN M IWANICKI	US 20200024618	A1	2020-01-23	
		1f		MALI PRASHANT G				
2	Altering a target nucleic acid in a cell by introducing into the cell a first foreign nucleic acid encoding guide RNA sequences complementary to DNA, and introducing into the cell a second foreign nucleic acid encoding a Cas9 protein	1g	HARVARD COLLEGE	BYRNE, Susan M.	US 20150140664 A1	BYRNE S M	CHURCH G M	Alteration of a target nucleic acid in a cell comprises introducing into the cell a first foreign nucleic acid encoding one or more guide RNA sequences complementary to DNA, where the DNA includes the target nucleic acid, introducing into the cell a second foreign nucleic acid encoding a Cas9 protein that binds to the DNA and is guided by the one or more guide RNA sequences, introducing into the cell a third foreign nucleic acid encoding an exogenous nucleic acid sequence to be included into the target nucleic acid sequence. [CONT.]
		1h		CHURCH, George M.				
		1i						
		2a						
		2b						
		2c						
		2d						
		2e						
		2f						
		2g						
		2h						
		2i						
		2j						
		2k						
3	New bacteriophage comprising polynucleotide that expresses RNA-directed DNA-binding polypeptide and targeting module comprising guide RNA, used e.g. for treating autoimmune and inflammatory disease, and disease caused by bacterial infection	2l	ZYMERGEN	LIU OLIVER	WO 2015070193 A1		KIM JEFFREY	(WO2015/070193) The present disclosure relates to engineered bacteriophage vector compositions comprising nucleic acids that express recombinant nucleases. Also provided are methods of using engineered bacteriophage vectors to effect genomic disruption or targeted gene disruption in prokaryotes. The disclosed compositions and methods are useful for reducing antibiotic resistance in bacteria cells.
		2m						
		2n						
		2o						
		2p						
		2q						
		2r						
		2s						
		2t						
		2u						
4	COMPOSITIONS AND METHODS FOR TARGETED GENE DISRUPTION IN PROKARYOTES	3a	HARVARD COLLEGE	CHURCH GEORGE M	US 9267135 B2		MALI PRASHANT G	(US9267135) Methods of modulating expression of a target nucleic acid in a cell are provided including introducing into the cell a first foreign nucleic acid encoding one or more RNAs complementary to DNA, wherein the DNA includes the target nucleic acid, introducing into the cell a second foreign nucleic acid encoding a nuclease-null Cas9 protein that binds to the DNA and is guided by the one or
		3b		ESVELT KEVIN M				
		3c						
		3d						
		3e						
		3f						
		3g						
		3h						
		3i						
		3j						
4	COMPOSITIONS AND METHODS FOR TARGETED GENE DISRUPTION IN PROKARYOTES	4a	RADIANT GENOMICS; RADIANT GENOMICS INC	LIU OLIVER	US 20150132263		Kim Jeffrey	The present disclosure relates to engineered bacteriophage vector compositions comprising nucleic acids that express recombinant nucleases. Also provided are methods of using engineered bacteriophage vectors to effect genomic disruption or targeted gene disruption in prokaryotes. The disclosed compositions and methods are useful for reducing antibiotic resistance in bacteria cells.
		4b						

# Export changes - Excel publisher links

VERSION

5.8

	Title	Patent Number	Patent Assignee	Inventor(s)	Abstract
1	<a href="#">Link</a> <b>Altering a target nucleic acid encoding one or more guide RNA sequences complementary to DNA, where the DNA includes the target nucleic acid, introducing into the cell a first foreign nucleic acid encoding one or more guide RNA sequences complementary to DNA, where the DNA includes the target nucleic acid, introducing into the cell a second foreign nucleic acid encoding a Cas9 protein that binds to the DNA and is guided by the one or more guide RNA sequences, introducing into the cell a third foreign nucleic acid encoding an exogenous nucleic acid sequence to be included into the target nucleic acid sequence.</b>		HARVARD COLLEGE BYRNE S M CHURCH G M	BYRNE, Susan M. CHURCH, George M.	Alteration of a target nucleic acid in a cell comprises introducing into the cell a first foreign nucleic acid encoding one or more guide RNA sequences complementary to DNA, where the DNA includes the target nucleic acid, introducing into the cell a second foreign nucleic acid encoding a Cas9 protein that binds to the DNA and is guided by the one or more guide RNA sequences, introducing into the cell a third foreign nucleic acid encoding an exogenous nucleic acid sequence to be included into the target nucleic acid sequence. [CONT.]
2			EMERGEN	LIU OLIVER KIM JEFFREY	(WO2015/070193) The present disclosure relates to engineered bacteriophage vector compositions comprising nucleic acids that express recombinant nucleases. Also provided are methods of using engineered bacteriophage vectors to effect genomic disruption or targeted gene disruption in prokaryotes. The disclosed compositions and methods are useful for reducing antibiotic resistance in bacteria cells.
3	<a href="#">Link</a> <b>RNA-guided transcriptional regulation</b>	US 9267135 B2	HARVARD COLLEGE	CHURCH GEORGE M MALI PRASHANT G ESVELT KEVIN M	(US9267135) Methods of modulating expression of a target nucleic acid in a cell are provided including introducing into the cell a first foreign nucleic acid encoding one or more RNAs complementary to DNA, wherein the DNA includes the target nucleic acid, introducing into the cell a second foreign nucleic acid encoding a nuclease-null Cas9 protein that binds to the DNA and is guided by the one or [CONT.]
4	<a href="#">Link</a> <b>COMPOSITIONS AND METHODS FOR TARGETED GENE DISRUPTION IN PROKARYOTES</b>	US 20150132263	RADIANT GENOMICS; RADIANT GENOMICS INC	LIU OLIVER Kim Jeffrey	The present disclosure relates to engineered bacteriophage vector compositions comprising nucleic acids that express recombinant nucleases. Also provided are methods of using engineered bacteriophage vectors to effect genomic disruption or targeted gene disruption in prokaryotes. The disclosed compositions and methods are useful for reducing antibiotic resistance in bacteria cells.

# Export changes - Excel headers

VERSION

5.8

sequences2019							
	Title	Database	Sequence ID	Patent Sequence Location	Score	Patent Family (Patent : Kind : Date)	Patent Assignee
1	New chitin binding protein (CBP21) protein or fusion protein useful in preparation of chitin combined functional product, chitinase enzyme activity function product, purified chitin and promoted chitinase enzyme.	Derwent GeneSeq		Example 1; Page 6	44 2% of query self score 2022	CN 103450352 : A : 20131218	(FEED-N) FEED RES INST CHINESE ACAD AGRIC SCI.
2	Use of recombinant bacteria for reducing and/or inhibiting the activity of YrrN protein and YwpE protein in Bacillus subtilis.	Derwent GeneSeq			40 2% of query self score 2022	CN 106282079 : A : 20170104	(CAGS) FEED RES INST CHINESE ACAD AGRIC SCI.
3	New chitin binding protein (CBP21) protein or fusion protein useful in preparation of chitin combined functional product, chitinase enzyme activity function product, purified chitin and promoted chitinase enzyme.	Derwent GeneSeq			46 2% of query self score 2022	CN 103450352 : A : 20131218	(FEED-N) FEED RES INST CHINESE ACAD AGRIC SCI.
4	New chitin binding protein (CBP21) protein or fusion protein useful in preparation of chitin combined functional product, chitinase enzyme activity function product, purified chitin and promoted chitinase enzyme.	Derwent GeneSeq	CN103450352-0002	Disclosure; SEQ ID NO. 2	963 47% of query self score 2022	CN 103450352 : A : 20131218	(FEED-N) FEED RES INST CHINESE ACAD AGRIC SCI.

More “Excel like”  
Filtering works as expected

☒ Include links to publisher website

☐ Include chart title

# Export changes - sequence alignments

- Sequence alignments display properly in Excel now

Alignment				
Q:	1	GY-Y-HWN	6	
S:	+	4	GYSYMHWN	11
Q:	1	GNIDNSASTNYNPSLKT	17	
S:	51	GNIFNSGSTNYNPSLKS	67	

# Styles for Summary Records

VERSION

5.8

1.	<b>Title:</b> New aryl sulfoxide derivatives useful for controlling animal pests in crop protection and/or in veterinary sector			
	<b>Database:</b> Derwent World Patents Index <a href="#">PatBase</a>			
	<b>Use:</b> (I) or the composition is useful for controlling animal pests in crop protection and/or in the veterinary sector (claimed).			
	<b>Probable Assignee:</b> BAYER CROPSOURCE AG			
	<b>Patent Family:</b>	<b>Patent</b>	<b>Kind</b>	<b>Date</b>
		<a href="#">WO 2014202510</a>	A1	2014-12-24
		TW 201536739	A	2015-10-01
	<b>Hyperlinks:</b>	<a href="#">Source</a>	<a href="#">WO 2014202510 A1</a>	<a href="#">PatDocs Family Tree</a>
Notes				

2.	<b>Title:</b> Composition for reducing overall damage of plants caused by insects, nematodes and phytopathogens comprises isolated <b>gougerotin (I)</b> and insecticide which is other than <b>gougerotin</b>														
	<b>Database:</b> Derwent World Patents Index Derwent World Patents Index <a href="#">PatBase</a>														
	<b>Use:</b> The composition is useful: as a fungicide and/or insecticide for reducing overall damage of plants and plant parts and losses in harvested fruits or vegetables caused by insects, nematodes and/or phytopathogens; for treating conventional or transgenic plants (all claimed); for improving stress tolerance against drought, heat, salt, UV, and improving root growth, root size maintenance, root effectiveness, and plant growth details are described but no results given.														
	<b>Probable Assignee:</b> BAYER CROPSOURCE LP														
	<table><tr><td><b>Patent Family:</b></td><td><table><tr><th>Patent</th><th>Kind</th><th>Date</th></tr><tr><td><a href="#">WO2014124373</a></td><td>A1</td><td>20140814</td></tr><tr><td><a href="#">US20140228213</a></td><td>A1</td><td>20140814</td></tr><tr><td>CA2899334</td><td>A1</td><td>20140814</td></tr></table></td></tr></table>	<b>Patent Family:</b>	<table><tr><th>Patent</th><th>Kind</th><th>Date</th></tr><tr><td><a href="#">WO2014124373</a></td><td>A1</td><td>20140814</td></tr><tr><td><a href="#">US20140228213</a></td><td>A1</td><td>20140814</td></tr><tr><td>CA2899334</td><td>A1</td><td>20140814</td></tr></table>	Patent	Kind	Date	<a href="#">WO2014124373</a>	A1	20140814	<a href="#">US20140228213</a>	A1	20140814	CA2899334	A1	20140814
<b>Patent Family:</b>	<table><tr><th>Patent</th><th>Kind</th><th>Date</th></tr><tr><td><a href="#">WO2014124373</a></td><td>A1</td><td>20140814</td></tr><tr><td><a href="#">US20140228213</a></td><td>A1</td><td>20140814</td></tr><tr><td>CA2899334</td><td>A1</td><td>20140814</td></tr></table>	Patent	Kind	Date	<a href="#">WO2014124373</a>	A1	20140814	<a href="#">US20140228213</a>	A1	20140814	CA2899334	A1	20140814		
Patent	Kind	Date													
<a href="#">WO2014124373</a>	A1	20140814													
<a href="#">US20140228213</a>	A1	20140814													
CA2899334	A1	20140814													
	<table><tr><td><b>Hyperlinks:</b></td><td><table><tr><td><a href="#">Source</a></td><td><a href="#">WO 2014124368 A1</a></td><td><a href="#">PatDocs Family Tree</a></td></tr></table></td></tr></table>	<b>Hyperlinks:</b>	<table><tr><td><a href="#">Source</a></td><td><a href="#">WO 2014124368 A1</a></td><td><a href="#">PatDocs Family Tree</a></td></tr></table>	<a href="#">Source</a>	<a href="#">WO 2014124368 A1</a>	<a href="#">PatDocs Family Tree</a>									
<b>Hyperlinks:</b>	<table><tr><td><a href="#">Source</a></td><td><a href="#">WO 2014124368 A1</a></td><td><a href="#">PatDocs Family Tree</a></td></tr></table>	<a href="#">Source</a>	<a href="#">WO 2014124368 A1</a>	<a href="#">PatDocs Family Tree</a>											
<a href="#">Source</a>	<a href="#">WO 2014124368 A1</a>	<a href="#">PatDocs Family Tree</a>													
	Notes														

Summary Record Export Options

The Summary Record export shows the columns (fields) visible in your chart.

☒ Number the records

☐ Start each record on new page

☐ Skip empty fields in records

☒ Include Links section

☒ Include PatDocs links

☒ Include editable Notes section

☒ Include Index of Hit Structures

You may also include the following information for the record:

☒ Include Claims

☐ Include Alignment

☐ Include Hit Structures

☒ Include Index Terms

You may select a visual style for the export:

Color - original style with yellow boxes

Color - original style with yellow boxes

Simple - clean style without color backgrounds

Open

Save

Cancel


derivatives useful for controlling animal pests in crop protection, and/or in veterinary sector	
ex	
useful for controlling animal pests in crop protection, material protection and/or in the	
G	
<b>Id</b>	<b>Date</b>
	2014-12-24
	2015-10-01
A1	<a href="#">PatDocs Family Tree</a>
reducing overall damage of plants caused by insects, mites, nematodes comprises isolated <b>gougerotin (I)</b> and at least one insecticide which	
tin	
ex	
ex	
as a fungicide and/or insecticide for reducing overall damage of plants and plant parts	
its or vegetables caused by insects, mites, nematodes and/or phytopathogens; for	
transgenic plants or its seed (all claimed); for improving stress tolerance against drought,	
old; and improving root growth, root size maintenance, root effectiveness, and plant	
cribed but no results given.	
b	
<b>Id</b>	<b>Date</b>
	20140814
	20140814
	20140814
A1	<a href="#">PatDocs Family Tree</a>

# Agenda

- What we do
- Roadmap
- Exports
- **Reference Rows**
- Sources
- Questions and Requests

# Reference Rows Workflow Improvements

- No wizard (go directly to the selection view)
- Chart does not need to be saved
- Chart can come from a single database




Combined: MCC Combined - March 2021

	Drug Name	Common Drug Name	Database	Developer	Highest Phase (Normalized)	Therapeutic Activity	Route of Admin	Update Date
1	ADUS-100	ADUS-100	GlobalData Drugs	Chinook Therapeutics Inc	Discontinued	L03AX Other immunostimulants	Intratumor Intravesical	2020-11-26
2	ALRN-6924	ALRN-6924	GlobalData Drugs	Aileron Therapeutics Inc	Phase 2	L01XX Other antineoplastic agents	Intravenous	2021-03-04
3 a	nogapendekin alfa	ALT 803	GlobalData Drugs	Altor Bioscience LLC	Phase 3	J05AR Antivirals for treatment of HIV infections, combinations L03AC Interleukins	Intraperitoneal Intravenous Intravesical Parenteral Subcutaneous	2021-03-25
3 b	Inbakicept - ImmunityBio	ALT 803	Adis R&D Insight	Altor BioScience Corporation (Originator) NantKwest (Originator)	Phase 2/3	J1X (Other Antibacterials) J5 (Antivirals for Systemic Use) L1X (All Other Antineoplastics) L1X9 (All other antineoplastics) L3A (Immunostimulating Agents Excluding Interferons)	Intraperitoneal Intravesicular IV Parenteral SC	2021-03-11
	ALT 803	ALT 803	Cyteline	Altor BioScience	Phase 2	Fusion protein	Injectable	2020-12-24

## Reference Rows Workflow Improvements (2)

- Quick preview to see how rules work
- Opens an HTML export in your browser using your last export settings



	Title	Common Family	Basic Patent Number	Inventor(s)	Patent Assignee	Hit PatentPak	
						RN	Location
1.	Benzoxaborole compounds and uses thereof	WO 2016128949	WO 2016128949 A1	Alley, M. R. K. Barros-Aguirre, David Giordano, Ilaria Hernandez, Vincent Li, Xianfeng Plattner, Jacob J.	GlaxoSmithKline Intellectual Property (No.2) Limited, UK Anacor Pharmaceuticals, Inc.	1655492-02-6P	Pg 85
	1 CA		1 CA	1 CA	1 CA		1 CA
2.	Tricyclic benzoxaborole compounds and uses thereof	WO 2015021396	WO 2015021396 A2	Alley, M. R. K. Hernandez, Vincent S. Plattner, Jacob J. Li, Xianfeng Barros-Aguirre, David Giordano, Ilaria	GlaxoSmithKline Intellectual Property (No.2) Limited, UK Anacor Pharmaceuticals, Inc.	1655492-02-6P	Pg 62
	2 CA		2 CA	2 CA	2 CA		2 CA

# Reference Rows Appearance Changes

New Selection Glyphs


Singleton rows have simple row numbers

Source rows now have a letter instead of a decimal number

Combined: MCC Combined - March 2021				
	Drug Name	Common Drug Name	Database	Developer
1	ADUS-100	ADUS-100	GlobalData Drugs	Chinook Therap Inc
2	ALRN-6924	ALRN-6924	GlobalData Drugs	Aileron Therape
3 a	nogapendekin alfa	ALT 803	GlobalData Drugs	Altor Bioscienc
3 b	Inbakicept - ImmunityBio	ALT 803	Adis R&D Insight	Altor BioScienc Corporation (Or NantKwest (Ori
3 c	ALT 803	ALT 803	Citalin	Altor BioScienc


## Hide Reference Rows

- The #1 most requested feature in BizInt Smart Charts is now here! **Hide Reference Row**
- Right click on any component row in a Reference Row to hide the entire group.
- All rows are hidden when you return to Smart Charts



## View | Reference Rows

- With View | Reference Rows you can **hide**, **show**, and **rearrange** the Reference Rows in your chart
- The green number on some rows is the number of visible source rows in the group.



# Reference Rows Appearance / Export

VERSION

5.8

- Exports from Reference Rows used to have just one style

	Title	Common Family	Basic Patent Number	Inventor(s)	Patent Assignee	Hit PatentPak	
						RN	Location
1.	Benzoxaborole compounds and uses thereof	WO 2016128949	WO 2016128949 A1	Alley, M. R. K. Barros-Aguirre, David Giordano, Ilaria Hernandez, Vincent Li, Xianfeng Plattner, Jacob J.	GlaxoSmithKline Intellectual Property (No.2) Limited, UK Anacor Pharmaceuticals, Inc.	1655492-02-6P	Pg 85
	1 CA		1 CA	1 CA	1 CA		1 CA
2.	Tricyclic benzoxaborole compounds and uses thereof	WO 2015021396	WO 2015021396 A2	Alley, M. R. K. Hernandez, Vincent S. Plattner, Jacob J. Li, Xianfeng Barros-Aguirre, David Giordano, Ilaria	Glaxosmithkline Intellectual Property (No.2) Limited, UK Anacor Pharmaceuticals, Inc.	1655492-02-6P	Pg 62
	2 CA		2 CA	2 CA	2 CA		2 CA

[www.bizint.com](http://www.bizint.com)

# Reference Rows Appearance / Export

VERSION

5.8

Title

Synthesis of indole antivirals binding to FABP4 treating coronavirus infections

Source Attribution Options

You can specify how the source of cells is shown in exports:

☐ Attribution in a separate row

☐ Attribution as text in the cell

☒ Do not attribute cell sources

OK

Cancel

Help...

Title

Synthesis of indole antivirals binding to FABP4 treating coronavirus infections

Row Shading

Specify how rows are shaded:

☐ Alternating shaded rows

☒ Alternate shading based on sort

☐ Plain rows separated by lines

OK

Cancel

Help...

	Title	Common Family	Database	US Patent Number	Patent Assignee	Inventor(s)
1	Synthesis of indole antivirals binding to FABP4 treating coronavirus infections	WO 2022010951	1 CA		Crescenta Biosciences, USA	Koyuncu, Emre Kim, Hahn Hotamisligil, G
2	Anti-RNA viral, including anti-coronavirus agent - substituted quinoxaline, pharmaceutical composition and applications	RU 2744429	2 CA		Asavi, LLS, USA	Ivashchenko, I Ivashchenko, Aleksandr Vas Savchuk, Niko Filippovich Ivashchenko, Aleksandrovn
3	Esters of quinoxaline 1, 4-di-N-oxide with cytotoxic activity on tumor cell lines based on nci-60 panel		3 CA		Centro de Biotecnologia Genomica, Instituto Politecnico Nacional, Reynosa, Mex.	Rivera, Gildar Shah, Syed S Ahmad Arrieta-Baez, Palos, Isidro Mongue, Anto Sanchez-Torre Enid
4	Preparation of 2(1H)-quinolinone derivatives having antimicrobial activity	WO 2018174288	4 CA	US 20210070747 A1	Taisho Pharmaceutical Co., Ltd., Japan	Amada, Hidea Otake, Norika Ushiyama, Fu Kim, Chunhae Takeuchi, Tom Tanaka, Nozo
5	Preparation of indole antivirals binding to FABP4 treating coronavirus infections	WO 2022010951	5 CA	US 20210070747 A1	Taisho Pharmaceutical Co., Ltd., Japan	Amada, Hidea Otake, Norika Ushiyama, Fu Kim, Chunhae Takeuchi, Tom Tanaka, Nozo

www.bizint.com

# Agenda

- What we do
- Roadmap
- Exports
- Reference Rows
- **Sources**
- Questions and Requests

## Patent Databases

*Provide data on patents filed worldwide*

- STN - STNext (also Classic & New STN)
- Questel Orbit.com
- Minesoft PatBase
- Derwent Innovation
- Clarivate Cortellis IP, CDDI Patents
- GQ LifeSciences LifeQuest
- PatSnap **Coming ... Soon?**



# Database Changes (STN)

- Added support for PSPI in CAplus and MARPAT

Family Status		Status	Patent Family Status			
Patent	Status		Patent	Kind	Status	Status Date
WO 2021203539 A1	Alive	Alive	WO 2021203539	A1	Alive	20211021
CN 111493266 A	Alive		CN 111493266	A	Alive	20201121
CN 111493266 B	Alive		CN 111493266	B	Alive	20211007

- Support Claims in CAplus
- Added support for INFULL, JPFULL, KRFULL, RUFULL
- Cleaned up handling for all fulltext files (esp. Claims)

## *Other Database Changes*

- Member List now appears as a separate field rather than adding the list to the family (PatBase publication level)
- Fixed problem with WO publication numbers in Cortellis Patents exports

# PatBase updates in Version 5.8

- Correctly translate US kind codes (and AU, CA, ...)

US 2003027821	A1	2003-02-06
US 6624161	B2	2003-09-23
US 2003195206	A1	2003-10-16
US 2008161301	A1	2008-07-03
US 7825113	B2	2010-11-02
US 7858617	B2	2010-12-28
US 2011065697	A1	2011-03-17
US 8877750	B2	2014-11-04

- Links to USPTO, Espacenet, and others work better

## *PatBase updates in Version 5.8*

VERSION

5.8

- Support for XML export  
(eventually this will be the new BizInt export)
- XML includes hit highlights (only one color in BizInt)
- Several new fields available
  - Master publication number
  - Standard Essential Patent, FDA data, etc.

## *PatBase updates in Version 5.8 (5.8.1?)*

VERSION

5.8

- Clean up Notes presentation
  - Get rid of extraneous line breaks
  - Get rid of language markup (except for machine translation)
  - Untruncated view in Summary Records

## IP Sequence Databases

*Provide data on sequences filed in patents*

- GenomeQuest (Geneseq, GQ-PAT, **virtual DBs**)
- STN (**USGENE**, **GENESEQ**, **PATGENE**)
- CAS Biosequences on GenomeQuest
- Orbit BioSequences
- Derwent SequenceBase



## *Recent Database Changes*

- Support for Virtual Databases on GenomeQuest  
Including full text search results
- Complete rework of sequence databases on STNext  
USGENE, GENESEQ, PATGENE  
**Only in BizInt export from STNext**



## Literature Databases

*Provide data on technical and scientific publications*

- **Biomedical** (Embase, Biosis, Medline)
- **Scientific** (SciSearch, Chemical Abstracts, PQSciTech, etc.)
- **Technical** (INSPEC, RAPRA, GEOREF, etc.)
- **Hosts:** STN (Classic & New), SciFinder, Dialog, Ovid, PubMed



# Clinical Trials Databases

Provide data on drug trials worldwide

**BizInt Smart Charts**

*Drug Development Suite*

## Commercial:

- Citeline TrialTrove 
- Adis Clinical Trials Insight
- Cortellis Trials Intelligence
- **GlobalData Clinical Trials**

## Public registries:

- ClinicalTrials.gov
- WHO ICTRP
- EU Clinical Trials (EudraCT)




# Drug Pipeline Databases

Provide data on drugs in development worldwide

**BizInt Smart Charts**

*Drug Development Suite*

- Citeline Pharmaprojects 
- IMS R&D Focus
- Adis R&D Insight
- Clarivate Cortellis
- Cortellis Drug Discovery Intelligence (Integrity)
- **GlobalData Pipeline Drugs**
- And, support for Infodesk PipelinePlus



# PatentPak Support

- Introduced in Version 5.7.1  
BizInt export only
- PatentPak Interactive link available as a column or in the summary records link section




CA Classification:			
Hyperlinks:	WO 2012033858 A2	<a href="#">PatDocs Family Tree</a>	<a href="#">PatentPak Interactive</a>
Notes			

- Hit PatentPak available as a column or in several places in the summary records export

# PatentPak Support

Hit PatentPak		Hit Index Terms PPAK		
RN	Location	RN	Role	Notes
1655492-02-6P	Pg 85	1655492-02-6P (Pg 85)	RL: RCT (Reactant); SPN (Synthetic preparation);	prepn. and anti-mycobacterial


## Index of Hit Structures

Substance	Structure	Reference
1 1655492-02-6 2,1-Benzoxaborole, 4-fluoro-1,3-dihydro-1-hydroxy-3-(nitromethyl)-7-[2-(phenylmethoxy)ethoxy]- (CA INDEX NAME)		prepn. and anti-mycobacterial activity of benzoxaborole compds. <a href="#">Reference 1 (Pg 85)</a>
1364682-96-1P 1364683-03-3P 1364684-69-4P 1364684-75-2P		prepn. and biol. applications of tricyclic benzoxaborole compds. <a href="#">Reference 2 (Pg 62)</a>

2 1364682-96-1  
1-Propanol, 3-[[[3-(aminomethyl)-4-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl]oxy]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

Hit Structures:

1655492-02-6 [\(Cmpd. 1\) \(Pg 62\)](#)  
2,1-Benzoxaborole, 4-fluoro-1,3-dihydro-1-hydroxy-3-(nitromethyl)-7-[2-(phenylmethoxy)ethoxy]- (CA INDEX NAME)



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
  
prepn. and biol. applications of tricyclic benzoxaborole compds.

Index Terms:

1655492-02-6P [\(Cmpd. 1\) \(Pg 62\)](#) RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. and biol. applications of tricyclic benzoxaborole compds.)

## *STNext BizInt Export*

- New BizInt Report format available on STNext
- Supported in Version 5.6
- More reliable field extraction
- Includes hit term highlights
- Can select answer sets, display commands, records
- [bizint.com/support/create/stnext.php](http://bizint.com/support/create/stnext.php)

www.bizint.com

# STNext BizInt Export

Reporting

Select L#s to Include

Clear

Expand All

▼

☒

L5 L3 AND L4

(86)

Select Field Template

Manage Custom Templates

☐ Journal

☐ Patent

☐ Patent and Journal

☐ Substance Report

Select Report Format

Hit Highlighting Options

☐ Standard

☐ Enhanced

☐ Table

☐ XML

☒ BizInt

www.bizint.com

# STNext Reports and Templates

EPFULL  
Record

BIB AB  
CLMEN

Patent  
Template

BizInt  
Definition

Columns

BizInt  
Chart

STNext

Transcript ON2022\_0013\_Transcript

File EPFULL

L5

ANSWER 1 OF 1 EPPULL COPYRIGHT 2022 LNU on STN.

AN

1992589 EPPULL EDP 20210308 ED 20210308 UP 20211125 EDTX 20210308 DED 20110331 DUPO 20211118 Full-text

TIE

PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS

TIFR

COMPOSES DE PYRAZOLO[3,4-B]PYRIDINE ET LEUR UTILISATION COMME INHIBITEURS DE PDE4

TIDE

PYRAZOLO[3,4-B]PYRIDINVERBINDUNGEN UND IHRE VERWENDUNG ALS PDE4-INHIBITOREN

IN

EDLIN, Christopher, David, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB  
HOLMAN, Stuart, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB  
JONES, Paul, Spencer, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB  
KEELING, Suzanne, Elaine, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB  
LINDVALL, Miska, Kristian, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB  
MITCHELL, Charlotte, Jane, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB  
TRIVEDI, Naimisha, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB

PA

GLAXO GROUP LIMITED, Glaxo Wellcome House, Berkeley Avenue,, Greenford, Middlesex UB6 0NN, GB

PAS

GLAXO GROUP

PAN

GLAXOSMITHKLINE

AG

Gladwin, Amanda Rachel, GlaxoSmithKline Corporate Intellectual Property CN925.1 980 Great West Road, Brentford, Middlesex TW8 9GS, GB

LAF

English

LA

English

DT


Patent; (Fulltext)

PI

EP 1940835 B1 20110330

DS

R: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC NL PT RO SE SK SI TR



	Drug	Common Drug Name	Database	Synonyms	Highest Phase	Companies	Last Update
1	Pretium	Pretium	Donec	Velut auctor Diam gravida Lobortis leo bibendum	Phase 3	Lobortis Turpis Aliquam Sodales	2012-11-17
2	Pretium XGS	Pretium	Loareet Sem	Velut auctor Diam gravida XS-2	Phase2	Lobortis Turpis Aliquam Sodales	2012-10-01
3	Sollicitudin 4S	Sollicitudin	Donec	Quam diam Augue sit Ametan id lacus	Phase 3	Egestas Condernum Lobortis Turpis	2011-12-07
4	Sollicitudin	Sollicitudin	Elitend-UR	Quam diam Augue sit Ametan id lacus	Phase 3	Egestas Condernum	2011-06-07
5	Etiam Mollis	Etiam Mollis	Loareet Sem	Adipiscing Proin Mattis Faucibus lacus	Phase 3	Condernum Est	2012-01-13
6	Etiam Mollis	Etiam Mollis	Elitend-UR	Adipiscing Et Sed Proin Mattis Faucibus	Phase 2	Condernum Est	2012-01-13
7	Toror Felis	Toror Felis	Donec	Aenean lectus purus Nulla sit amet Quisque placerat 2A	Phase 2	Loareet	2011-06-03
8	Toror Felis III	Toror Felis	Loareet Sem	Aenean lectus purus Quisque placerat	Phase 2	Loareet	2011-06-03
9	Consectetur	Consectetur	Donec	Purus non urna Ligula est Quam sem ac	Phase 3	Lobortis turpis	2012-03-01
10	Consectetur 2A	Consectetur	Nullam	Purus non urna Ligula est Quam sem ac	Phase 3	Lobortis turpis	2012-03-01

# STNext Reports and Templates

EPFULL  
Record

BIB AB  
CLMEN

Custom  
Template

BizInt  
Definition

Columns

BizInt  
Chart

STNext

Transcript ON2022\_0013\_Transcript

File EPPULL

L5

ANSWER 1 OF 1 EPPULL COPYRIGHT 2022 LNU on STN.

AN

1992589 EPPULL EDP 20210308 ED 20210308 UP 20211125 EDTX 20210308 DED 20110331 DUPO 20211118 Full-text

TIEN

PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS

TIFR

COMPOSES DE PYRAZOLO[3,4-B]PYRIDINE ET LEUR UTILISATION COMME INHIBITEURS DE PDE4

TIDE

PYRAZOLO[3,4-B]PYRIDINVERBINDUNGEN UND IHRE VERWENDUNG ALS PDE4-INHIBITOREN

IN

EDLIN, Christopher, David, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB  
HOLMAN, Stuart, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB  
JONES, Paul, Spencer, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB  
KEELING, Suzanne, Elaine, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB  
LINDVALL, Miska, Kristian, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB  
MITCHELL, Charlotte, Jane, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB  
TRIVEDI, Naimisha, GlaxoSmithKline Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY, GB

PA

GLAXO GROUP LIMITED, Glaxo Wellcome House, Berkeley Avenue,, Greenford, Middlesex UB6 0NN, GB

PAS

GLAXO GROUP

PAN

GLAXOSMITHKLINE

AG

Gladwin, Amanda Rachel, GlaxoSmithKline Corporate Intellectual Property CN925.1 980 Great West Road, Brentford, Middlesex TW8 9GS, GB

LAF

English

LA

English

DT


Patent: (Fulltext)

PI

EP 1940835 B1 20110330

DS

R: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC NL PT RO SE SK SI TR



	Drug	Common Drug Name	Database	Synonyms	Highest Phase	Companies	Last Update
1	Pretium	Pretium	Donec	Velut auctor Diam gravida Lobortis leo bibendum	Phase 3	Lobortis Turpis Aliquam Sodales	2012-11-17
2	Pretium XGS	Pretium	Loamet Sem	Velut auctor Diam gravida XS-2	Phase2	Lobortis Turpis Aliquam Sodales	2012-10-01
3	Sollicitudin 4S	Sollicitudin	Donec	Quam diam Augue sit Ametan id lacus	Phase 3	Egestas Condimentum Lobortis Turpis	2011-12-07
4	Sollicitudin	Sollicitudin	Elitend-UR	Quam diam Augue sit Ametan id lacus	Phase 3	Egestas Condimentum	2011-06-07
5	Etiam Mollis	Etiam Mollis	Loamet Sem	Adipiscing Proin Mattis Faucibus lacus	Phase 3	Condimentum Egest	2012-01-13
6	Etiam Mollis	Etiam Mollis	Elitend-UR	Adipiscing Et Ssc Proin Mattis Faucibus	Phase 2	Condimentum Egest	2012-01-13
7	Toror Felis	Toror Felis	Donec	Aenean lectus purus Nulla sit amet Quisque placerat 2A	Phase 2	Loamet	2011-06-03
8	Toror Felis III	Toror Felis	Loamet Sem	Aenean lectus purus Quisque placerat	Phase 2	Loamet	2011-06-03
9	Consectetur	Consectetur	Donec	Purus non urna Ugulae sit Quam sem ac	Phase 3	Lobortis turpis	2012-03-01
10	Consectetur 2A	Consectetur	Nullam	Purus non urna Ugulae sit Quam sem ac	Phase 3	Lobortis turpis	2012-03-01

## *Hit Term Highlights*

- Added support for hit term highlights in version 5.6.1
- Only available in the BizInt exports from STNext and Orbit.com
- Appear in the **backing records**
- Appear in record exports  
(including claims in summary records exports)
- PatBase support in XML export

VERSION

5.8

- [bizint.com/support/use/hit\\_highlight.php](http://bizint.com/support/use/hit_highlight.php)

# Hit Term Highlights

- Smart Charts records

Records: 5f19a5be-71c2-4b48-bc1a-e...

↑ ↓

2: Novel epoxide polyene amphoteric macrolide and process for purifying na

Novel epoxide polyene amphoteric macrolide and process for purifying **natamycin**

Patent Family

Patent	Kind	Date
EP 3837269	A1	2021-06-23
WO 202035553	A1	2020-02-20
US 20210188892	A1	2021-06-24
CN 112585150	A	2021-03-30

- Exports

| Record 2 of 72 | [Publisher Version](#) | [Back to chart](#) |


Novel epoxide polyene amphoteric macrolide and process for purifying **natamycin**

Patent Family

Patent	Kind	Date
EP 3837269	A1	2021-06-23
WO 202035553	A1	2020-02-20
US 20210188892	A1	2021-06-24
CN 112585150	A	2021-03-30

## Delete user-added columns


- Delete User Columns command
- Remove user-added and VP-SCE columns
- Can select multiple columns (don't worry - you can't accidentally delete publisher fields)



Update Date	
User	User comments (empty)
User	Untitled (empty)

# Hide Multiple Columns

- Select one or more columns
- View | Hide Column



ee	Inventor(s)	Abstract	Accession Number	Chemical Name	Cited Referer Count

Column Properties...

Add Column

Hide Column

Delete User Column

Sort...

Statistics...

Font...

Quick format >

Color cells Ctrl+L

Copy Ctrl+C

Paste Ctrl+V

Find... Ctrl+F

Find Next F3

Replace... Ctrl+R




# Color Coding Cells



Software for  
Business Intelligence

## BizInt Smart Charts

- Choice of eight colors for color coding added in Version 5.5



Common Drug Name	Database	Mech
ALT-803	Adis R&D Insight	Interleukin
ALT-803	Citeline Pharmaprojects	Interleukin Immuno-o
ALT-803	GlobalData Drugs	Cytokine R Subunit Ga Receptor S GammaC



THE JOURNEY CONTINUES...

Questions?  
Requests?



*We make tables*



## *Things down the road...*

- Record classification workflow
- Links, highlights, and multi-byte characters in both chart cells and records
- Custom records
- Permanently delete hidden rows
- Database Support
  - Refresh of Derwent Innovation support
  - More consistent support of Independent Claims

## *Roadmap: Subtable Editing Support*

- Features will apply to publisher and created subtables
- Sorting sub-rows
- Filtering
- Change sub-column selection
- Change sub-column titles, properties
- Edit subtables directly (no more copy/paste to notepad)
- Save user-created subtables in chart templates